Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772281 | 1.00 | HTR2B (0.51) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL23273841 | 0.86 | PRMT5 (0.45) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL29772268 | 0.86 | PRMT5 (0.45) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL29772276 | 0.84 | PRMT5 (0.55) | PRMT5METTL3 | |
| SCHEMBL23313202 | 0.84 | PRMT5 (0.55) | PRMT5METTL3 | |
| SCHEMBL29611607 | 0.83 | ADORA1 (0.54) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL27090409 | 0.83 | ADORA1 (0.54) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL24313826 | 0.79 | HTR2B (0.41) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL29611113 | 0.79 | HTR2B (0.41) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 | |
| SCHEMBL27090421 | 0.79 | HTR2B (0.41) | HTR2BSIGMAR1HTR1DTMEM97ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021079196-A9 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021079196-A9 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021079196-A2 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021079196-A2 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027361-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | HTR2B 2106/4885SIGMAR1 2376/4885HTR1D 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.